Articles

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University;Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne’s University Hospital
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University;Center of Molecular Medicine, Central European Institute of Technology, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University;Center of Molecular Medicine, Central European Institute of Technology, Masaryk University
Department of Histology and Embryology, Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne’s University Hospital;Department of Cytokinetics, Institute of Biophysics CAS, v.v.i.;Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne’s University Hospital;Department of Cytokinetics, Institute of Biophysics CAS, v.v.i.;Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University;Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne’s University Hospital
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
Vol. 104 No. 12 (2019): December, 2019 https://doi.org/10.3324/haematol.2018.203430